

Nemo Healthcare (Veldhoven, the Netherlands) enables improved fetal monitoring with the introduction of the Nemo Fetal Monitoring System.

After more than 10 years of research and development, Nemo Healthcare is proud to present the Nemo Fetal Monitoring System (NFMS), a breakthrough innovation that opens up new possibilities for fetal monitoring. The new product will be launched on November 20th, 2018, at the University Hospital Antwerp (UZA) in Belgium.

The NFMS is an innovative, wearable device that accurately monitors fetal and maternal heart rate and uterine activity, all from a single measurement. The NFMS supports healthcare professionals with information they need for safer births and healthier children.

“What we need is a non-invasive fetal monitoring system - also in the obese future - which provides high quality information and makes it possible to intervene in time, before damage occurs to the unborn child.”

Prof. Dr. Y. (Yves) Jacquemyn, UZA - University Hospital Antwerp.

The NFMS is designed to provide accurate information for reliable early diagnosis and monitoring in a safe and easy way. The system is non-invasive, and provides high quality measurements. It is easy to use, comfortable to wear (even showering) and wireless. The NFMS is delivered with two Nemo Links, which can be used alternately. Each Link will allow for up to at least 18 hours of recording. The Nemo Base is equipped with a rechargeable battery, allowing for stand-alone use, for example during transportation of the patient to the operating room.



The NFMS uses a dedicated, multi-surface electrode patch with 6 electrodes. Fetal and maternal heart rate are derived from the recorded combined ECG-signals, and uterine activity is derived from the EMG-signals when the uterine muscles contract. Proprietary algorithms in the Nemo Base convert the amplified and wirelessly transmitted electrophysiological signals from the Nemo Link to readable information as is normally visualised on the central monitoring system of the hospital.

The NFMS provides more reliable measurements compared to systems using traditional external sensors, furthermore the NFMS provides high-quality measurements even for the difficult to monitor obese women.

The NFMS comes with an (online) e-learning course to support the users in getting acquainted with this innovative technology. The NFMS is expected to reduce overall cost of care.

CE regulatory approval has been granted and the NFMS is commercially available as of November 2018. The first customer orders have already been received: “We are very excited to ship our first CE-certified systems to our customers and help them further improve care for the unborn child and mother as of this moment”, says Michiel Manuel, CEO of Nemo Healthcare.

About Nemo Healthcare
www.Nemohealthcare.com

Nemo Healthcare focusses on the improvement of fetal monitoring, based on electrophysiological signals, non-invasively recorded on the maternal abdomen. Nemo Healthcare was founded in 2010 as the result of joint research between Máxima Medical Center Veldhoven (MMC) and Eindhoven University of Technology (TU/e) and is based in Veldhoven (the Netherlands).